I was not suggesting we were getting to $10 on this run or this year. Just saying I think we will get to $10 long before we ever get FDA approval.
The $1.25 - $2.50 is quite possibly a short-term target, though I have not seen any logic laid out on any board as to why people are picking this range.
I will note for those who think $2.50 is some short-term top, that JJ has suggested through his interviews and presentations for some time that he thinks we should be valued at several hundred million instead of the current $40ish million. I personally agree with him and think that, if companies start to pursue us (instead of us pursuing them) a fair share price for us right now is $8-$10.
Market Data 
Markets 
AI
